- Home
- OKUR vs ALXO Comparison
OKUR vs ALXO Comparison
Compare OKUR & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKUR
- ALXO
- Stock Information
- Founded
- OKUR 2011
- ALXO 2015
- Country
- OKUR United States
- ALXO United States
- Employees
- OKUR N/A
- ALXO N/A
- Industry
- OKUR
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- OKUR
- ALXO Health Care
- Exchange
- OKUR NYSE
- ALXO Nasdaq
- Market Cap
- OKUR 75.5M
- ALXO 76.5M
- IPO Year
- OKUR N/A
- ALXO 2020
- Fundamental
- Price
- OKUR $5.74
- ALXO $1.32
- Analyst Decision
- OKUR Strong Buy
- ALXO Buy
- Analyst Count
- OKUR 4
- ALXO 6
- Target Price
- OKUR $35.00
- ALXO $6.64
- AVG Volume (30 Days)
- OKUR 135.4K
- ALXO 1.2M
- Earning Date
- OKUR 02-14-2025
- ALXO 03-06-2025
- Dividend Yield
- OKUR N/A
- ALXO N/A
- EPS Growth
- OKUR N/A
- ALXO N/A
- EPS
- OKUR N/A
- ALXO N/A
- Revenue
- OKUR N/A
- ALXO N/A
- Revenue This Year
- OKUR N/A
- ALXO N/A
- Revenue Next Year
- OKUR N/A
- ALXO N/A
- P/E Ratio
- OKUR N/A
- ALXO N/A
- Revenue Growth
- OKUR N/A
- ALXO N/A
- 52 Week Low
- OKUR $4.58
- ALXO $1.19
- 52 Week High
- OKUR $20.00
- ALXO $17.83
- Technical
- Relative Strength Index (RSI)
- OKUR N/A
- ALXO 40.06
- Support Level
- OKUR N/A
- ALXO $1.30
- Resistance Level
- OKUR N/A
- ALXO $1.56
- Average True Range (ATR)
- OKUR 0.00
- ALXO 0.15
- MACD
- OKUR 0.00
- ALXO -0.04
- Stochastic Oscillator
- OKUR 0.00
- ALXO 15.37
About OKUR ONKURE THERAPEUTICS INC
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.